Pharma, Planes, and Policies: Major Shifts in Global Business

This review covers GSK's potential $9 billion acquisition of Nuvalent, AstraZeneca's weight-loss drug trial results, Germany's withdrawal from a Franco-German fighter jet project, and the UK's lawsuit against Neil Woodford for unauthorized financial advice. These developments highlight significant changes in healthcare, defense, and financial sectors.

GSK, the UK pharmaceutical giant, is negotiating a potential $9 billion purchase of cancer biotech company Nuvalent, aiming to strengthen its oncology portfolio. Meanwhile, AstraZeneca has made strides in the weight-loss market, as trials show its GLP-1 pill, elecoglipron, helps participants lose significant weight.

In a blow to European defense cooperation, Germany has informed France of its intention to pull out of a collaborative fighter jet development program, signaling possible challenges ahead for Europe's defense strategy.

On the financial front, the UK's regulatory body has launched legal actions against Neil Woodford, accusing him of offering unauthorized investment advice through his digital service, W4.0, thus raising concerns about investor protections.